Active	Status	Sponsor type	Region	Phase	Filter
2 Active 6 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pfaar, Oliver
PREPARED-1, NCT06339008: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis	Recruiting	3	450	Europe, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Perennial Allergic Rhinitis (PAR)	10/25	02/27
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP	Completed	3	276	Europe, Canada, Japan, US, RoW	Depemokimab (GSK3511294), Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nasal Polyps	07/24	08/24